Introduction
============

High morbidity and mortality from severe sepsis and septic shock is still an unresolved challenging \[[@b1-kjccm-2017-00094],[@b2-kjccm-2017-00094]\]. Sepsis-induced tissue hypoperfusion and organ dysfunction result from vasodilation, decreased systemic vascular resistance, and increased microvascular leakage \[[@b3-kjccm-2017-00094]\]. Hypotension triggers a complex neurohumoral response during severe sepsis to maintain blood pressure homeostasis, resulting in increased sympathetic responses and hypothalamic--pituitary--adrenal axis stimulation \[[@b4-kjccm-2017-00094]\]. The lack of this response in critically ill patients is related to a poor prognosis \[[@b5-kjccm-2017-00094],[@b6-kjccm-2017-00094]\].

To preserving blood pressure homeostasis, the renin-angiotensin-aldosterone system (RAAS) is required. By loss of blood volume or a drop in blood pressure, RAAS induces hormonal activation sequentially with renin-angiotensin I-angiotensin II-aldosterone. This sophisticated system controls microvascular, blood pressure, and organ function \[[@b7-kjccm-2017-00094]\], as well as inflammatory responses. The dissociation of plasma renin activity (PRA) and aldosterone production, namely hyperreninemic hypoaldosteronism, has been observed in approximately 20%--30% of critically ill patients, increasing the development of acute renal failure, other organ dysfunction, and death \[[@b8-kjccm-2017-00094]\]. Plasma aldosterone concentrations (PACs) are useful biomarker to detect septic shock patients with a high risk of renal dysfunction \[[@b8-kjccm-2017-00094]\].

However, little is known regarding the usefulness of PRA and PAC measurements in prediction of mortality or relations with mortality in patients with septic shock. We hypothesized that prolonged septic shock increases PRA and PACs, resulting in increased inflammatory activity, organ failure, and mortality. In this study, we examined whether PRA and PAC measurement compared with conventional severity indicators are associated with 28-day mortality in patients with septic shock.

Materials and Methods
=====================

1) Study design and setting
---------------------------

This study was a prospective blood sampling and retrospective data analysis of a cohort of patients admitted to the medical intensive care unit (ICU) from August 2008 to January 2009. We enrolled 140 patients aged older than 19 years who had been admitted to the ICU with septic shock from August 2008 to January 2009. All of the patients met the following criteria for septic shock, as established by the International Sepsis Definitions Conference \[[@b9-kjccm-2017-00094]\]: (1) clinical diagnosis of septic shock made within the past 48 hours with a documented bacterial infection and (2) at least two of the following: fever (body temperature, \>38°C) or hypothermia (\<36°C), heart rate \>90 beats min^-1^, respiratory rate \>20 breaths min^-1^, white blood cell count \>12,000 cells mm^-3^ or \<4,000 cells mm^-3^, or \>10% immature (band) forms. Patients also had to meet the additional following criteria for septic shock: the presence of at least two signs of organ dysfunction (metabolic acidosis, arterial hypoxemia \[PaO~2~/FiO~2~ ratio \<250\], oliguria \[\<30 ml kg^-1^ for 3 hours\], intravascular disseminated coagulopathy, or an abrupt change in mental status); and persistent hypotension with systolic blood pressure of \<90 mmHg for at least 1 hour, despite adequate fluid replacement (assessed by a central venous pressure \>8 mmHg) and continuous administration of inotropic or vasopressor support \[[@b9-kjccm-2017-00094]\].

We excluded two patients without PAC or PRA measurements. We also excluded 33 patients who had previously taken angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (n = 12), who previously took aldosterone antagonists (n = 5), who had a history of steroid usage (n = 12), and who had previously used hemodialysis (n = 4). A total of 105 patients were included in the study. Demographic, clinical, and biochemical data at the time of ICU admission were recorded. Baseline characteristics are shown in [Table 1](#t1-kjccm-2017-00094){ref-type="table"} and [Figure 1](#f1-kjccm-2017-00094){ref-type="fig"}.

2) Data collection
------------------

To assess the severity of illness and prognosis of the underlying disease, the Acute Physiology and Chronic Health Evaluation (APACHE) II score and Sequential Organ Failure Assessment (SOFA) score were evaluated at the initial time of ICU admission. The SOFA score was also recorded on days 1, 3, and 7. Data of the following parameters were also collected: age, sex, total fluid input and output, serum creatinine levels, arterial blood gas analysis, and serum electrolytes. Additionally, patients were assessed with respect to their need for mechanical ventilation, ventilator-free days, and/or renal replacement therapy. All of the patients were evaluated over their entire ICU stay, and ICU-free days and outcomes were recorded. The definitions of ventilator free-days and ICU free-days are as follows:

Ventilator free-days = number of days from day 1 to day 28 on which a patient breathed without assistance (if the period of unassisted breathing lasted at least 48 consecutive hours)

ICU free-days = number of days from day 1 to day 28 on which a survived patient is not in ICU

3) Plasma biomarker sampling
----------------------------

Blood samples were collected with the patient in the supine position in the early morning. On the day of sampling, blood samples were immediately sent to a laboratory for measuring biomarkers, such as PACs (by radioimmunoassay; normal range, 29.9 to 158.8 ng dl^-1^; Cobra II gamma counter, Hewlett-Packard, Meriden City, KS, USA), PRA (by radioimmunoassay; normal range, 0.15 to 2.23 ng ml^-1^ h^-1^; Cobra II gamma counter, Hewlett-Packard), plasma cortisol levels (by comparative binding immunoenzymatic assay; normal range, 6.7 to 22.6 pg ml^-1^; UNICEL DXI 800, Beckman Coulter Inc., Brea, CA, USA), and C-reactive protein (CRP) levels (by immunoturbidimetry; normal range, 0 to 8.0 mg L^-1^; Hitachi 7600, Sekisui, Japan). Serial PACs, PRA, the PAC/PRA ratio, cortisol levels, and CRP levels were measured on days 1, 3, and 7 to analyze changes over time. Based on the previous study, the definition of hyperreninemic hypoaldosteronism was defined when PAC/PRA ratio was less than 2 \[[@b8-kjccm-2017-00094]\].

4) Statistical analyses
-----------------------

Continuous variables are presented as the mean ± standard deviation or median (interquartile range) and categorical variables as number (percentage) of the total sample. Baseline characteristics of the groups were compared using the χ^2^ test or Fisher exact test for categorical variables. And nonnormally distributed variables were compared using the Mann-Whitney U-test, and normally distributed variables using Student t-test when analyzing continuous variables. Pearson correlation was performed to investigate the relationships between SOFA scores and PRA or PACs. We evaluated 28-day all-cause mortality as the study endpoint. We conducted receiver operating characteristic (ROC) analysis to compare the predictive accuracy of PRA or PACs and APACHE II scores or SOFA scores. The area under the curve (AUC) was calculated. The Youden index was used to determine the optimal cutoff value of PRA or PACs for predicting 28-day mortality. Survival curves were prepared using the Kaplan-Meier method, and comparisons were made using the log-rank test. Prognostic variables for mortality were analyzed using the univariate Cox proportional hazards model, and variables with P-values \<0.1 were used in the multivariate Cox proportional hazard model with backward selection. Results of univariate and multivariate Cox regression analyses are presented as hazard ratios and 95% confidence intervals (CIs). Differences were considered statistically significant at P \< 0.05 (two-tailed). Statistical analyses were performed using the SPSS software package version 18.0 (SPSS Inc., Chicago, IL, USA).

5) Ethics statement
-------------------

The protocol was approved by our institutional review board (No. 4-2008-0099). Written informed consent was obtained from the patients or their next of kin.

Results
=======

1) Baseline characteristics of the study population
---------------------------------------------------

A total of 105 patients with septic shock were enrolled. There were 65 (61.9%) men and 40 (38.1%) women. The mean age was 63.6 years (range, 55 to 74 years). The 28-day mortality was 43.8% (n = 46) and these patients were classified as non-survivors. The remaining patients were classified as survivors. [Table 1](#t1-kjccm-2017-00094){ref-type="table"} shows the comparison of demographics and clinical parameters on day 1 between non-survivors and survivors. Age, sex, primary infection site, the rate of positive blood culture, the comorbidities are similar in both groups. However, the survivor group showed lower APACHE II scores (P = 0.001) and SOFA scores (P = 0.001), and a much more prevalent history of coronary arterial occlusive disease or cancer than did the non-survivor group. In terms of critical care needs, patients in the non-survivor group had less ventilator-free days (P \< 0.001) and ICU-free days (P \< 0.001), and required a higher number of steroid use and continuous renal replacement therapy applications within 7 days after admission than did those in the non-survivor group. The non-survivor group showed a higher heart rate (P = 0.036) and net fluid balance on day 1 (P = 0.022), but a lower PaO~2~/FiO~2~ ratio (P = 0.002), than did the survivor group. The survivor group showed significantly lower PRA (P = 0.003) and PACs (P = 0.008) than did the non-survivor group. However, there were no significant differences in other blood biomarkers, such as CRP levels, cortisol levels, and the PAC/PRA ratio, between the non-survivor and survivor groups ([Tables 1](#t1-kjccm-2017-00094){ref-type="table"} and [2](#t2-kjccm-2017-00094){ref-type="table"}).

2) Time course of PRA and PACs during the first 7 ICU days in the non-survivor and survivor groups
--------------------------------------------------------------------------------------------------

The time course of PRA in he survivors and non-survivors was as follows. PRA and PACs in the survivors were significantly lower than in the non-survivors on days 1, 3, and 7 ([Figure 2](#f2-kjccm-2017-00094){ref-type="fig"}, [Supplementary Table 1](#SD1-kjccm-2017-00094){ref-type="supplementary-material"}). PACs were significantly lower in the survivor group than in the non-survivor group on days 1 (P = 0.008), 3 (P = 0.001), and 7 (P = 0.012). CRP levels, cortisol levels, and the PAC/PRA ratio were not different between the non-survivor and survivor groups on day 1, 3, and 7 ([Supplementary Table 1](#SD1-kjccm-2017-00094){ref-type="supplementary-material"}). When serial PAC, PRA, cortisol, and CRP level were measured, PAC and PRA level were consistently lower in the surviving group, but CRP and cortisol level were not ([Supplementary Table 1](#SD1-kjccm-2017-00094){ref-type="supplementary-material"}).

3) Correlations between PRA or PACs and the APACHE II score and SOFA score
--------------------------------------------------------------------------

PRA was positively correlated with the APACHE II score (r = 0.230, P = 0.018) and the SOFA score (r = 0.373, P \< 0.001) ([Figure 3A](#f3-kjccm-2017-00094){ref-type="fig"} and [B](#f3-kjccm-2017-00094){ref-type="fig"}). PACs were only positively correlated with the SOFA score (r = 0.316, P = 0.001) ([Figure 3C](#f3-kjccm-2017-00094){ref-type="fig"} and [D](#f3-kjccm-2017-00094){ref-type="fig"}). However, both biomarkers showed weak positive correlation.

4) Risk analysis for 28-day mortality
-------------------------------------

The areas under the ROC curve for PRA and PAC values on day 1 were 0.69 (95% CI, 0.58 to 0.79; P = 0.001) and 0.67 (95% CI, 0.56 to 0.77; P = 0.003), respectively. These values were similar to the APACHE II scores (AUC, 0.68; 95% CI, 0.58 to 0.78; P = 0.001) and SOFA scores (AUC, 0.67; 95% CI, 0.57 to 0.77; P = 0.003) ([Figure 4](#f4-kjccm-2017-00094){ref-type="fig"}). Therefore, based on the maximal value of the Youden index (J = 0.25), the most discriminatory markers were PRA with a cutoff of 3.5 ng ml^-1^ h^-1^ (sensitivity of 76.1% and specificity of 64.4%) and PAC with a cutoff of 112 ng dl^-1^ (sensitivity of 58.7% and specificity of 71.2%) for predicting 28-day mortality. Kaplan-Meier survival analysis showed that the 28-day mortality of patients with PRA values ≥3.5 ng ml^-1^ h^-1^ (n = 49) was higher than that of patients with PRA values \<3.5 ng ml^-1^ h^-1^ (n = 56) (log-rank test, P \< 0.001, [Figure 5](#f5-kjccm-2017-00094){ref-type="fig"}). Using Cox regression analysis, PRA and PACs, as well as several other clinical characteristics to predict 28-day mortality, were evaluated ([Table 3](#t3-kjccm-2017-00094){ref-type="table"}). After adjusting for confounding factors, the SOFA score (hazard ratio, 1.11; 95% CI, 1.01 to 1.22), PRA values ≥3.5 ng ml^-1^ h^-1^ (hazard ratio, 3.25; 95% CI, 1.60 to 6.60), previous history of cancer (hazard ratio, 3.44; 95% CI, 1.72 to 6.90) and coronary arterial occlusive disease (hazard ratio, 2.99; 95% CI, 1.26 to 7.08) were independently associated with 28-day mortality.

Discussion
==========

In the current study, we assessed clinical parameters, including serial serum PRA and PACs of septic shock patients on days 1, 3, and 7 after admission to ICU in a single-center cohort. The main findings of this study were as follows: (1) 28-day survivors showed lower PRA and PAC values than did 28-day non-survivors; (2) PRA and PACs were positively correlated with severity scores; and (3) in particular, patients with septic shock with PRA values ≥3.5 ng ml^-1^ h^-1^ on day 1 were related to 28-day mortality.

APACHE II score or SOFA score are used as a good indicator of the severity stratification or prognosis predication of patients with sepsis in the ICU. In our study, PRA and PACs were positively correlated with the SOFA score on days 1, 3, and 7. Their prognostic accuracy was similar to that of SOFA scores for mortality. PRA values ≥3.5 ng ml^-1^h^-1^ on day 1 was identified as an independent factor associated with 28-day mortality, even after adjusting for other parameters and severity scores (APACHE II and SOFA score). Although a single biomarker cannot substitute a composite indicator of severity such as APACHE II score or SOFA score, our findings may help to understand the pathophysiology in septic shock. And these results could be explained as follows. Over the last decade, new components of the RAAS have been found to be involved in many essential pathophysiological processes, such as development, inflammation, and remodeling \[[@b10-kjccm-2017-00094],[@b11-kjccm-2017-00094]\]. Recently, the relevance between the potentially proinflammatory effects of angiotensin II and the pathogenesis of sepsis and acute lung injury has been of interest \[[@b12-kjccm-2017-00094]-[@b14-kjccm-2017-00094]\]. Blocking of a pro-renin receptor attenuates an inflammatory response in an animal model of sepsis using rat \[[@b15-kjccm-2017-00094]\]. Many serum markers in the inflammatory cascade have been assessed in sepsis as potential indicators of infection \[[@b16-kjccm-2017-00094]\]. In particular, the RAAS plays important roles in controlling blood pressure, microvascular regulation, and organ function, as well as in inflammatory responses. In our study, there was a positive linear correlation between PRA or PACs and the organ failure score (SOFA score) in septic shock patients. We initially expected that elevated PRA or PACs may also contribute to a stronger inflammatory response and may be a similarly useful prognostic indicator as serial CRP measurements in prediction of infection \[[@b17-kjccm-2017-00094]\] and in monitoring treatment responses \[[@b18-kjccm-2017-00094]-[@b20-kjccm-2017-00094]\]. However, there was no linear correlation between PRA or PACs and CRP levels. Further studies are required to determine the role of PRA and PACs in the inflammatory response using other inflammatory markers.

This was the first study to elucidate the relationship between PRA and mortality in patients with septic shock. There have been no studies on the association between PRA and mortality in patients with septic shock. However, in animal experiments, there is evidence between RAAS activity and sepsis \[[@b11-kjccm-2017-00094]\]. In some studies, hyperreninemic hypoaldosteronism has been identified as a potential prognostic indicator of septic shock-induced acute renal failure \[[@b8-kjccm-2017-00094]\] and liver cirrhosis \[[@b21-kjccm-2017-00094]\]. du Cheyron et al. \[[@b8-kjccm-2017-00094]\] showed that hyperreninemic hypoaldosteronism might be related with acute kidney injury in patients with septic shock. In our study, 55.2% of patients with septic shock had hyperreninemic hypoaldosteronism. du Cheyron et al. \[[@b8-kjccm-2017-00094]\] found hyperreninemic hypoaldosteronism in 48% of septic shock patients, which is similar to our study. However, we did not find any correlations between hyperreninemic hypoaldosteronism and any clinical outcome, such as renal failure, ventilator-free days, ICU-free days, and 28-day mortality (data not shown). Similar to our study, du Cheyron et al. \[[@b8-kjccm-2017-00094]\] also found that patients with septic shock showed markedly elevated PRA levels, associated with volume depletion and catecholamine-induced stimulation of β-adrenergic receptors. In our study, the non-survivor group showed higher PRA and PACs than did the survivor group, despite a greater net fluid balance on day 1. This finding suggests that patients with higher PRA and PACs need much more fluid administration for intravascular volume depletion than expected. In our data, PRA was consistently higher in non-survival group ([Figure 2A](#f2-kjccm-2017-00094){ref-type="fig"}). Therefore, mortality in septic shock patients may be relevant with prolonged plasma renin activation not merely hyperreninemic hypoaldosteronism defined as a fixed cutoff (PAC/PRA \<2).

The effects of the RAAS are no longer considered to be limited to the circulatory system. This is because system components are also produced and activated *in situ* in other tissues, including the brain, blood vessels, adrenals, adipose tissue, kidney, and heart, acting through paracrine and autocrine mechanisms \[[@b22-kjccm-2017-00094]\]. In particular, angiotensin II can promote cell growth and inflammation by enhancing expression of endothelium-derived adhesion molecules \[[@b23-kjccm-2017-00094]\] and production of pro-inflammatory cytokines and chemokines \[[@b24-kjccm-2017-00094]\]. Angiotensin II also has procoagulant activity \[[@b25-kjccm-2017-00094]\], and can stimulate reactive oxygen species production \[[@b26-kjccm-2017-00094]\]. This results in increased microvascular hydraulic permeability \[[@b27-kjccm-2017-00094]\] and capillary leakage in severe sepsis. Doerschug et al. \[[@b7-kjccm-2017-00094]\] showed that PRA was correlated with plasma concentrations of angiotensin II, microvascular dysregulation, and organ failure in patients with septic shock. Accordingly, long-term RAAS over-activation may be harmful in patients with severe sepsis and septic shock, regardless of hyperreninemic hypoaldosteronism. In our serial follow-up data (day 1, day 3, and day 7), consistently high PRA levels were observed in non-survivor groups. And we found the relation between high PRA level and mortality in septic shock in Cox regression model. Therefore we support a negative effect on survival in septic shock patients by long-term RAAS over-activation. Hirano et al. \[[@b15-kjccm-2017-00094]\] showed that a (pro) renin receptor blocker significantly improved survival in rats with clinically relevant sepsis induced through cecal ligation and puncture. However, further human data on RAAS activity in sepsis are required. In a practical situation, it may be important to identify the appropriate time and subject to receive a RAAS antagonist because of the beneficial role of angiotensin II in maintaining vascular tone during septic shock. Our study showed that renin activity ≥3.5 ng ml^-1^ h^-1^ was significantly correlated with 28-day mortality in patients with septic shock. This finding can be used as the basis for selection of (pro) renin blocker candidates for future clinical studies. Interestingly, Vergaro et al. \[[@b28-kjccm-2017-00094]\] showed that a cutoff value for PRA ≥2.3 ng ml^-1^ h^-1^ was the best predictor of cardiac mortality in patients with heart failure, which is similar to our finding. In future studies, cutoff values for PRA should be investigated in various diseases.

We are aware of some limitations of our research. First, this small, single-center, retrospective cohort study should not be generalized. Large-scale, multicenter, prospective validation studies are required to confirm these findings. Although this was a retrospective cohort study, we attempted to remove confounding factors from the data, such as prior use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone antagonists, and steroids, as well as the effect of terminal renal failure. Second, we did not perform adrenocorticotropic hormone stimulation tests to assess the adequacy of adrenal function. This is a major limitation, even though an adrenocorticotropic hormone stimulation test is usually not recommended in patients with septic shock \[[@b29-kjccm-2017-00094]\]. In addition, no data about thyroid function test can affect the results of our study. Third, we did not examine plasma angiotensin II concentrations because angiotensin II are not correlated with SOFA score in the later course of sepsis \[[@b7-kjccm-2017-00094]\]. Additionally, a previous study showed that angiotensin II activity is only correlated with organ failure only during initial treatment. However, we wished to evaluate PRA and PACs over the course of septic shock. Fourth, in this study, the ROC AUC of APACHE II and SOFA score were relatively low because it may be due to the difference in the timing of beginning of septic shock and the time of admission to the ICU. And elevated PRA levels cannot be generalized to the entire sepsis patients because our study was aimed only at patients with septic shock. These points required careful interpretation. Finally, we only assessed CRP as an inflammatory marker with PRA and PACs. We did not measure blood lactate levels, procalcitonin, or prothrombin time for inflammation or coagulation system. Other biomarkers may show different results.

In conclusion, based on our findings, elevated PRA might be a useful prognostic biomarker for risk stratification of patients with septic shock, and an indicator of 28-day mortality. Therefore, the results of our study support that PRA can be a potential therapeutic target. In the future, multicenter, large-scale studies on RAAS inhibition, such as PRA antagonists may be needed for septic shock treatment.

No potential conflict of interest relevant to this article was reported.
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![Flow chart of inclusion and exclusion of patients in the study. A total of 140 patients were enrolled between August and December 2008, and 105 patients were included in the analysis. Patients without available renin and aldosterone measurements (n = 2), those using an angiotensinconverting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) (n = 12), those using an aldosterone antagonist (n = 5), those using steroids (≥15 mg/d) (n = 12), and those who had previous usual hemodialysis (n = 4) within 7 days were excluded. ICU: intensive care unit.](kjccm-2017-00094f1){#f1-kjccm-2017-00094}

![Time courses of PRA and PACs in non-survivors versus survivors. Levels of PRA (A) and PACs (B) were measured on days 1, 3, and 7 after admission. The circles and bars indicate the mean values and SEM, respectively. Significant differences between nonsurvivors and survivors are indicated by an asterisk (\*P \< 0.05, survivors versus non-survivors on each day). PRA: plasma renin activity; PAC: plasma aldosterone concentration; SEM: standard error of the mean.](kjccm-2017-00094f2){#f2-kjccm-2017-00094}

![Correlations between PRA or PAC, SOFA score, and APACHE II score on day 1. The PRA levels correlated with better with APACHE II score (A) or SOFA score (B) than the PAC levels (C, D) although there were weak correlations. The open circles indicate survivors, and the solid circles indicate non-survivors. APACHE: Acute Physiologic and Chronic Health Evaluation; PRA: plasma renin activity; SOFA: Sequential Organ Failure Assessment; PAC: plasma aldosterone concentration.](kjccm-2017-00094f3){#f3-kjccm-2017-00094}

![Receiver operating characteristic curves for PRA and PAC on day 1 for predicting 28-day mortality. The prognostic accuracy of PRA and PAC was not inferior to that of the APACHE II and SOFA scores. APACHE: Acute Physiologic and Chronic Health Evaluation; AUC: area under the curve; CI: confidence interval; SOFA: Sequential Organ Failure Assessment; PRA: plasma renin activity; PAC: plasma aldosterone concentration.](kjccm-2017-00094f4){#f4-kjccm-2017-00094}

![Kaplan-Meier survival curves for 28 days according to PRA. The cutoff value was the optimal cutoff limit that predicted 28-day mortality (PRA \<3.5 ng/ml/h or ≥3.5 ng/ml/h). PRA: plasma renin activity; ICU: intensive care unit.](kjccm-2017-00094f5){#f5-kjccm-2017-00094}

###### 

Baseline characteristics according to 28-day mortality

  Characteristic                              Non-survivors (n = 46 \[43.8\])   Survivors (n = 59 \[56.2\])   P-value
  ------------------------------------------- --------------------------------- ----------------------------- ---------
  Age (yr)                                    65.0 (54.0--73.3)                 65.0 (56.0--74.0)             0.824
  Male sex                                    28 (60.9)                         37 (62.7)                     1.000
  APACHE II score                             26.0 (23.8--31.0)                 22.0 (18.0--28.0)             0.001
  SOFA score                                  9.0 (7.0--12.3)                   7.0 (4.0--10.0)               0.001
  Comorbidity                                                                                                 
   CAOD                                       7 (15.2)                          2 (3.4)                       0.040
   Hypertension                               13 (28.3)                         28 (47.5)                     0.069
   Diabetes                                   10 (21.7)                         21 (35.6)                     0.137
   Heart failure                              6 (13.0)                          6 (10.2)                      0.760
   Chronic lung disease                       7 (15.2)                          11 (18.6)                     0.795
   Chronic renal disease                      6 (13.0)                          6 (10.2)                      0.760
   Chronic liver disease                      12 (26.1)                         9 (15.3)                      0.220
   Cancer                                     35 (76.1)                         24 (40.7)                     \<0.001
  Primary site of infection                                                                                   0.814
   Pulmonary                                  34 (73.9)                         41 (69.5)                     
   Pancreato-biliary                          1 (2.2)                           5 (8.5)                       
   Liver                                      4 (8.7)                           3 (5.1)                       
   GI tract                                   2 (4.3)                           3 (5.1)                       
   Soft tissue and bone                       1 (2.2)                           1 (1.7)                       
   Brain and CSF                              0                                 1 (1.7)                       
   Kidney                                     1 (2.2)                           1 (1.7)                       
   Urogenital                                 1 (2.2)                           3 (5.1)                       
   Miscellaneous                              2 (4.3)                           1 (1.7)                       
  Positive blood culture                      17 (37.0)                         18 (30.5)                     0.535
  Acute renal failure                                                                                         0.489
   At risk                                    11 (23.9)                         15 (25.4)                     
   Injury                                     9 (19.6)                          14 (23.7)                     
   Failure                                    3 (6.5)                           8 (13.6)                      
  Chronic renal disease acute exacerbation,   6 (13.0)                          6 (10.2)                      0.760
  Steroid use within 7 days                   29 (63.0)                         24 (40.7)                     0.031
  No. of CRRT applied within 7 days           18 (39.1)                         10 (16.9)                     \<0.001

Values are presented as number (%) or median (interquartile range).

APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; CAOD: coronary arterial occlusive disorder; CSF: cerebrospinal fluid; CRRT: continuous renal replacement therapy.

###### 

Clinical and biological characteristics according to 28-day mortality

  Variable                          Non-survivor (n = 46 \[43.8\])   Survivor (n = 59 \[56.2\])   P-value
  --------------------------------- -------------------------------- ---------------------------- ---------
  Mechanical ventilation used       43 (93.5)                        49 (83.1)                    0.140
  Heart rate (beats min^-1^)        120.0 (90.5--136.5)              105.0 (81.0--126.0)          0.036
  Mean arterial pressure (mmHg)     69.2 (62.8--92.6)                79.0 (65.7--99.3)            0.129
  pH                                7.4 (7.3--7.5)                   7.4 (7.3--7.5)               0.395
  PaCO~2~ (mmHg)                    35.7 (29.5--41.0)                32.2 (27.4--36.6)            0.320
  P/F ratio                         197.7 (150.7--257.9)             264.6 (180.5--365.5)         0.002
  PEEP (cmH~2~O)                    10.0 (8.0--12.0)                 10.0 (6.0--12.0)             0.679
  Platelet (10^3^/µl)               128.0 (52.5--227.8)              159 (76.0--314.0)            0.278
  Serum potassium (mmol L^-1^)      3.8 (3.4--4.6)                   3.7 (3.3--4.1)               0.301
  Serum sodium (mmol L^-1^)         137.0 (134.8--144.0)             138.0 (134.0--142.0)         0.279
  Blood urea nitrogen (mg dl^-1^)   24.7 (16.2--40.1)                25.6 (15.6--41.0)            0.853
  Serum creatinine (µmol L^-1^)     1.3 (0.7--1.9)                   1.2 (0.9--2.2)               0.760
  Ejection fraction (%)             66.0 (54.0--70.0)                66.0 (60.0--70.0)            0.551
  Net fluid balance at 1 days (L)   2.0 (0.5--3.4)                   1.0 (0.2--2.3)               0.022
  Blood Biomarkers                                                                                
   CRP (mg L^-1^)                   14.3 (5.8--28.7)                 13.8 (8.3--23.3)             0.578
   Cortisol (pg ml^-1^)             23.8 (15.2--46.0)                25.0 (15.8--45.3)            0.210
   PRA (ng ml^-1^h^-1^)             8.7 (3.2--23.4)                  2.4 (0.7--7.9)               0.003
   PAC (ng dl^-1^)                  125.9 (37.0--255.9)              53.8 (23.0--135.7)           0.008
   PAC/PRA ratio                    1.2 (0.6--3.0)                   1.9 (0.7--5.9)               0.581
   PAC/PRA \<2                      23 (50.0)                        35 (59.3)                    0.429

Values are presented as number (%) or median (interquartile range).

P/F: PaO~2~/FIO~2~; PEEP: positive end-expiratory pressure; CRP: C-reactive protein; PRA: plasma renin activity; PAC: plasma aldosterone concentration.

###### 

Univariate and multivariate Cox model for 28-day mortality in patients with septic shock

  Covariable                   Univariate analysis   Multivariate analysis                                    
  ---------------------------- --------------------- ----------------------- --------- ------- -------------- ---------
  APACHE II score              1.073                 1.028--1.121            0.001                            
  SOFA score                   1.169                 1.082--1.263            \<0.001   1.112   1.011--1.224   0.029
  Previous cancer history      3.140                 1.591--6.197            0.001     3.442   1.717--6.899   \<0.001
  CAOD history                 2.645                 1.179--5.935            0.018     2.989   1.263--7.075   0.013
  Steroid use within 7 days    1.945                 1.068--3.542            0.030                            
  CRRT within 7 days           2.290                 1.265--4.147            0.006     1.769   0.924--3.385   0.085
  Heart rate                   1.011                 1.000--1.022            0.048                            
  Net fluid balance at day 1   1.000                 1.000--1.000            0.011                            
  PaO~2~/FIO~2~ ratio          0.998                 0.995--1.001            0.130                            
  PRA ≥3.5 ng/ml/h             3.943                 1.996--7.790            \<0.001   3.245   1.596--6.597   0.001
  PAC ≥112 ng/dl               2.642                 1.466--4.760            0.001                            

HR: hazard ratio; CI: confidence interval; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; CAOD: coronary artery obstructive disease; CRRT: continuous renal replacement therapy; PRA: plasma renin activity; PAC: plasma aldosterone concentration.
